Effective 1 de noviembre de 2021, for commercial products, criteria used for medical necessity review of the following tests can be found in this medical policy and will no longer be in the online authorization tool: Breast Cancer Index, Prosigna, MammaPrint and EndoPredict. Please refer to the draft medical policy for coding and other details here.